Ebola Vaccine Still Effective When Highly Diluted, Study Shows


According to investigators at the National Institutes of Health, a single dose of highly diluted VSV-Ebola virus (EBOV) vaccine is still protective against the disease.

A single dose of highly diluted VSV-Ebola virus (EBOV) vaccine is still protective against the disease, according to investigators at the National Institutes of Health.

Since August 2018, 250,000 people have received the investigational VSV-EBOV vaccine as a part of a “ring vaccination” program. This program is intended to help stem the outbreak.

Researchers analyzed cynomolgus macaques and an updated vaccine component to match the EBOV strain that circulated in West Africa from 2014-2016. The VSV-EBOV vaccine is based on a live-attenuated vesicular stomatitis virus, delivering an EBOV protein to elicit a protective immune response.

Several dosage strengths were tested, including a strength with 10 million plaque-forming units (PFU). Macaques were vaccinated 28 days prior to infecting them with a lethal dose of EBOV. The animals were monitored for 42 days after the initial infection, and macaques given the lowest dose appeared completely protected from the disease due to EBOV.

Scientists concluded that their findings could help make more vaccines available for more people and may reduce adverse reactions to the vaccine, including injection site irritation, headache, fever, and chills.


Candidate ebola vaccine still effective when highly diluted, macaque study finds. NIH website. https://www.nih.gov/news-events/news-releases/candidate-ebola-vaccine-still-effective-when-highly-diluted-macaque-study-finds. Published October 18, 2019. Accessed October 21, 2019.

Related Videos
Image Credit: © Anastasiia - stock.adobe.com
Image Credit: © Анастасія Стягайло - stock.adobe.com
breast cancer treatment/Image Credit: © Siam - stock.adobe.com
small cell lung cancer treatment/Image Credit: © CraftyImago - stock.adobe.com
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
Mid-section portrait of unrecognizable woman during last months of pregnancy holding her big belly gently standing against wall in blue room - Image credit: pressmaster | stock.adobe.com
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.